Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.42 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.42 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.42 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701813 | 0.79 | TMEM97 (0.55) | TAAR1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6561077 | 0.79 | TAAR1 (0.55) | TAAR1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL28849471 | 0.79 | GFER (0.52) | ALDH1A1CA12CA1CA2 | |
| SCHEMBL6562213 | 0.79 | ALDH1A1 (0.50) | TAAR1HPGDCYP1A2ALDH1A1CA12 | |
| SCHEMBL5535468 | 0.79 | TAAR1 (0.50) | TAAR1PLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL349780 | 0.78 | ALDH1A1 (0.52) | TAAR1L3MBTL1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1486307 | 0.78 | LMNA (0.47) | HPGDL3MBTL1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6562364 | 0.76 | KCNJ1 (0.50) | HPGDCA12CA1CA2CA4 | |
| SCHEMBL5420659 | 0.76 | FFAR1 (0.48) | TAAR1 | |
| SCHEMBL1302121 | 0.75 | TDP1 (0.46) | L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0384362-B1 | Glycinderivatives | HOFFMANN LA ROCHE (CH) | 1999-12-15 | — | — | EP | claimed |
| US-5663297-A | OLIGOPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1997-09-02 | — | — | US | claimed |
| US-8247602-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| EP-1085009-B1 | INDAN DERIVATIVES | NISSAN CHEMICAL IND LTD (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-6486178-B1 | Indane derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| US-5663297-A | OLIGOPEPTIDES | HOFFMANN-LA ROCHE INC. (US) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016029-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | TAAR1 417/4885HPGD 23/4885L3MBTL1 4068/4885 |
| US-20110144160-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | TAAR1 417/4885HPGD 23/4885L3MBTL1 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.